BSPED2024 Poster Presentations Diabetes 5 (8 abstracts)
Strategizing early detection and follow-up for type 1 diabetes: The EDENT1FI project
Rachel Besser 1 , Jurgen Vercauteren 2 , Lut Overbergh 2 , Ezio Bonifacio 3 , Parth Narendran 4 , Regine Bergholdt 5 , Thorsten Strube 6 , Colin Dayan 7 , Elisabeth Niemoeller 6 , Emanuele Bosi 8 , Flemming Pociot 9 , Esther Latres 10 , Carmen Hurtado 10 , João Filipe. Raposo 11 , Marie Baccara-Dinet 12 , Felix Reschke 13 , Kamille Fogh 5 , Ohad Cohen 14 , Mark Peakman 15 , Anette Ziegler 16 & Chantal Mathieu 2
1University of Oxford, Oxford, United Kingdom; 2Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium; 3Dresden Technical University, Dresden, Germany; 4University of Birmingham, Birmingham, United Kingdom; 5Novo Nordisk, Soeborg, Denmark; 6Sanofi, Frankfurt, Germany; 7Cardiff University School of Medicine, Cardiff, United Kingdom; 8San Raffaele Scientific Institute, Milan, Italy; 9Steno Diabetes Center, Copenhagen, Denmark; 10Breakthrough T1D, New York, USA; 11APDP, Lisbon, Portugal; 12Sanofi, Paris, France; 13HKA, Hannover, Germany; 14Medtronic, Tolochenaz, Switzerland; 15Sanofi, Boston, USA; 16Helmholtz Zentrum Munich, Munich, Germany
Background and aims: European action for the Diagnosis of Early Non-clinical Type 1 diabetes For disease Interception (EDENT1FI) targets early Type 1 Diabetes (T1D) detection to reduce the risk of diabetic ketoacidosis, delay disease progression, improve long-term health outcomes and provide a ‘softer landing’ to insulin therapy. It aims to refine screening and support in early-diagnosed individuals to allow implementation in the clinical care setting.
Materials and methods: EDENT1FI includes 13 countries, including the United Kingdom (UK), and combines partnerships between academia, industry, clinical and patient groups. EDENT1FI aims to screen 200,000 general population children using islet autoantibody testing to detect 600 children with early-stage T1D. Antibody-positive children are followed up according to a novel risk-based approach.
Results: EDENT1FI (www.edent1fi.eu) comprises six work packages (WP). WP1 establishes screening programs across Europe and the UK, aligning with international recommendations and leveraging insights from previous studies. WP2 evaluates the psychosocial and economic impact of screening and addresses ethical considerations. WP3 focuses on follow-up. We will use the Progression Likelihood Score, which combines HbA1c, islet autoantigen-2 (IA-2A) and a 90-minute stimulated glucose, to inform a risk-stratified approach to follow-up, using home glucose testing, HbA1c, continuous glucose monitoring (CGM) and oral glucose tolerance testing (OGTT). The UK leads on assessing ‘light touch’ minimally invasive approaches to follow-up to reduce patient burden (capillary OGTT and proinsulin: C-peptide). WP4 develops a roadmap for preventive and disease-modifying approaches, utilizing adaptive trial designs. WP5 emphasizes effective communication and dissemination strategies. WP6 ensures effective project management and governance. Embedded within the programme is a patient advisory group who advises on all aspects of the programme. Data from people with early-stage T1D throughout Europe will be collected in a pseudonymised manner in EDENT1FI-REGISTRY, and in the UK through the UK-Islet autoantibody registry.
Conclusion: EDENT1FI represents a pioneering effort to advance early detection of T1D. By leveraging multidisciplinary expertise, international and industry collaboration, the project aims to change the pathway to diagnosis in T1D and improve outcomes for children and adolescents at risk of developing T1D.
Volume 103
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more